More Diagnostics, Inc. Signs an Agreement with Emery Pharma

More Diagnostics, Inc., an employee owned developer and manufacturer of clinical diagnostic controls and Emery Pharma, a full-service contract research & development organization, specializing in microbiology, cell biology medicinal chemistry and bioanalytical services, announced the signing of a four-year agreement with Emery Pharma to provide Liquid Chromatography Mass Spectrometry (LC-MS) services to More Diagnostics. The agreement covers the analysis of the full range of analytes available in the controls for immunoassays used for testing immunosuppressant drugs, such as Everolimus, Tacrolimus, Cyclosporine and Sirolimus (Rapamycin).

"We are very pleased to team with Emery Pharma as our partner in maintaining the highest level of quality and integrity of our products and collaborate with us the on-going development of new products," commented Endre Vargha, CEO of More Diagnostics.